Roche Strengthens Cancer Diagnostic Portfolio With Launch of Test for Differential Diagnosis of Mesothelioma
October 29, 2026
October 29, 2026
BASEL, Switzerland, Oct. 29 (TNSjou) -- Roche, a biotech company, issued the following news release:
* * *
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
October 28, 2026
* The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen.
* Most patients are d . . .
* * *
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
October 28, 2026
* The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen.
* Most patients are d . . .
